Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATAI NASDAQ:DNLI NASDAQ:INDV NASDAQ:RXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATAIatai Life Sciences$4.52-1.5%$3.61$1.03▼$5.34$981.67M1.555.40 million shs3.83 million shsDNLIDenali Therapeutics$15.31-0.9%$14.52$10.57▼$33.33$2.23B1.231.69 million shs2.80 million shsINDVIndivior$24.67+0.3%$19.47$7.33▼$25.00N/A0.812.35 million shs2.25 million shsRXRXRecursion Pharmaceuticals$4.63-0.6%$5.42$3.79▼$12.36$2.04B0.9116.66 million shs12.57 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATAIatai Life Sciences-1.53%-1.09%+6.10%+82.26%+270.49%DNLIDenali Therapeutics-0.91%-1.86%+6.02%+7.67%-39.05%INDVIndivior+0.28%+1.27%+16.26%+81.53%+102.71%RXRXRecursion Pharmaceuticals-0.64%-5.32%-20.17%+1.31%-23.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATAIatai Life Sciences3.5053 of 5 stars4.63.00.00.02.11.70.6DNLIDenali Therapeutics4.3288 of 5 stars3.61.00.04.74.33.30.0INDVIndivior2.9557 of 5 stars1.64.00.00.02.91.73.1RXRXRecursion Pharmaceuticals2.1056 of 5 stars3.21.00.00.02.22.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATAIatai Life Sciences 3.17Buy$11.25148.89% UpsideDNLIDenali Therapeutics 3.12Buy$33.62119.56% UpsideINDVIndivior 3.17Buy$22.00-10.82% DownsideRXRXRecursion Pharmaceuticals 2.40Hold$7.2556.59% UpsideCurrent Analyst Ratings BreakdownLatest ATAI, INDV, RXRX, and DNLI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/27/2025INDVIndiviorCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$27.00 ➝ $34.008/20/2025ATAIatai Life SciencesZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/18/2025DNLIDenali TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$33.00 ➝ $30.008/6/2025INDVIndiviorHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$27.007/30/2025ATAIatai Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $15.007/29/2025ATAIatai Life SciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$14.007/28/2025ATAIatai Life SciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $11.007/28/2025DNLIDenali TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/22/2025INDVIndiviorJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.007/8/2025RXRXRecursion PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.007/3/2025RXRXRecursion PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight$5.00(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATAIatai Life Sciences$310K3,125.22N/AN/A$0.67 per share6.75DNLIDenali Therapeutics$330.53M6.77N/AN/A$7.02 per share2.18INDVIndivior$1.19BN/A$1.85 per share13.34($2.52) per shareN/ARXRXRecursion Pharmaceuticals$58.84M34.16N/AN/A$2.12 per share2.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATAIatai Life Sciences-$149.27M-$0.69N/AN/AN/AN/A-85.43%-64.38%11/12/2025 (Estimated)DNLIDenali Therapeutics-$422.77M-$2.80N/AN/AN/AN/A-40.79%-36.39%11/5/2025 (Estimated)INDVIndivior$2M$0.6239.7914.43N/A6.65%-86.28%16.26%10/23/2025 (Estimated)RXRXRecursion Pharmaceuticals-$463.66M-$1.78N/AN/AN/A-1,004.91%-76.09%-54.29%11/5/2025 (Estimated)Latest ATAI, INDV, RXRX, and DNLI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ATAIatai Life Sciences-$0.12-$0.14-$0.02-$0.14N/A$0.72 million8/11/2025Q2 2025DNLIDenali Therapeutics-$0.74-$0.72+$0.02-$0.72$5.64 millionN/A8/5/2025Q2 2025RXRXRecursion Pharmaceuticals-$0.35-$0.41-$0.06-$0.41$15.38 million$19.10 million7/31/2025Q2 2025INDVIndivior$0.26$0.51+$0.25$0.14$239.43 million$302.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATAIatai Life SciencesN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATAIatai Life Sciences0.024.024.02DNLIDenali Therapeutics0.0110.2710.27INDVIndiviorN/A0.900.76RXRXRecursion Pharmaceuticals0.023.583.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATAIatai Life Sciences28.41%DNLIDenali Therapeutics92.92%INDVIndivior60.33%RXRXRecursion Pharmaceuticals89.06%Insider OwnershipCompanyInsider OwnershipATAIatai Life Sciences26.80%DNLIDenali Therapeutics12.50%INDVIndiviorN/ARXRXRecursion Pharmaceuticals8.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATAIatai Life Sciences80214.34 million156.90 millionOptionableDNLIDenali Therapeutics430146.21 million127.94 millionOptionableINDVIndivior1,051N/AN/ANot OptionableRXRXRecursion Pharmaceuticals400434.15 million397.55 millionOptionableATAI, INDV, RXRX, and DNLI HeadlinesRecent News About These CompaniesRecursion Pharmaceuticals, Inc. (RXRX) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 3 at 8:03 PM | seekingalpha.comJump Financial LLC Increases Position in Recursion Pharmaceuticals, Inc. $RXRXAugust 29, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (RXRX) Expands Rare Disease Pipeline with REV102 AcquisitionAugust 28, 2025 | insidermonkey.comRecursion to Participate in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comContrasting Recursion Pharmaceuticals (NASDAQ:RXRX) and Organogenesis (NASDAQ:ORGO)August 27, 2025 | americanbankingnews.com1,912,620 Shares in Recursion Pharmaceuticals, Inc. $RXRX Purchased by Nuveen LLCAugust 25, 2025 | marketbeat.comNeedham Maintains Buy Rating on Recursion (RXRX)August 24, 2025 | msn.comThe Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to ExplodeAugust 23, 2025 | fool.comRecursion Pharmaceuticals, Inc. $RXRX Stock Position Reduced by Vanguard Group Inc.August 23, 2025 | marketbeat.comWhy Recursion Pharmaceuticals Stock Caught a Cold This WeekAugust 22, 2025 | fool.comRecursion Pharmaceuticals (RXRX) Sees Sales And Revenue Growth In Q2 2025August 22, 2025 | finance.yahoo.comInsider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Insider Sells 36,599 Shares of StockAugust 21, 2025 | marketbeat.comRecursion Pharmaceuticals (RXRX) Drops on 3rd Day as Company Execs Dispose of SharesAugust 21, 2025 | insidermonkey.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.3% - Here's WhyAugust 20, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Insider Najat Khan Sells 36,599 SharesAugust 20, 2025 | insidertrades.comEverSource Wealth Advisors LLC Raises Stake in Recursion Pharmaceuticals, Inc. $RXRXAugust 20, 2025 | marketbeat.comLPL Financial LLC Purchases 57,305 Shares of Recursion Pharmaceuticals, Inc. $RXRXAugust 20, 2025 | marketbeat.comRecursion: "Hold" Rating Based On Initial REC-4881 FAP Treatment DataAugust 19, 2025 | seekingalpha.comLiontrust Investment Partners LLP Lowers Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)August 18, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Sold by Vestmark Advisory Solutions Inc.August 18, 2025 | marketbeat.comRecursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical CandidAugust 17, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATAI, INDV, RXRX, and DNLI Company Descriptionsatai Life Sciences NASDAQ:ATAI$4.52 -0.07 (-1.53%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$4.56 +0.04 (+0.77%) As of 09/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.Denali Therapeutics NASDAQ:DNLI$15.31 -0.14 (-0.91%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$15.54 +0.23 (+1.47%) As of 09/3/2025 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Indivior NASDAQ:INDV$24.67 +0.07 (+0.28%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$24.83 +0.16 (+0.65%) As of 09/3/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Recursion Pharmaceuticals NASDAQ:RXRX$4.63 -0.03 (-0.64%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$4.64 +0.00 (+0.11%) As of 09/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
